Molecular Biomarker Validation Status for CBS/PSP

Migration, Crosslink

📖

Molecular Biomarker Validation Status for CBS/PSP

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-biomarkers-cbs-psp-biomarker-valida

📖 Wiki Page

biomarker1326 wordssynced 2026-04-02

Overview

flowchart TD biomarkers_cbs_psp_biomarker_v["Molecular Biomarker Validation Status for CBS/PS"] biomarkers_cbs_psp_biomarker_v["page"] biomarkers_cbs_psp_biomarker_v -->|"related to"| biomarkers_cbs_psp_biomarker_v style biomarkers_cbs_psp_biomarker_v fill:#81c784,stroke:#333,color:#000 biomarkers_cbs_psp_biomarker_v["tracks"] biomarkers_cbs_psp_biomarker_v -->|"related to"| biomarkers_cbs_psp_biomarker_v style biomarkers_cbs_psp_biomarker_v fill:#81c784,stroke:#333,color:#000 biomarkers_cbs_psp_biomarker_v["molecular"] biomarkers_cbs_psp_biomarker_v -->|"related to"| biomarkers_cbs_psp_biomarker_v style biomarkers_cbs_psp_biomarker_v fill:#81c784,stroke:#333,color:#000 biomarkers_cbs_psp_biomarker_v["corticobasal"] biomarkers_cbs_psp_biomarker_v -->|"related to"| biomarkers_cbs_psp_biomarker_v style biomarkers_cbs_psp_biomarker_v fill:#81c784,stroke:#333,color:#000 style biomarkers_cbs_psp_biomarker_v fill:#4fc3f7,stroke:#333,color:#000

This page tracks the validation status of molecular biomarkers for corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), two 4R-tauopathies within the atypical parkinsonism spectrum. Biomarker validation follows a phased approach from analytical validation through clinical implementation.

Biomarker Validation Framework

Validation Phase Definitions

...

Overview

Mermaid diagram (expand to render)

This page tracks the validation status of molecular biomarkers for corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), two 4R-tauopathies within the atypical parkinsonism spectrum. Biomarker validation follows a phased approach from analytical validation through clinical implementation.

Biomarker Validation Framework

Validation Phase Definitions

| Phase | Description | Key Activities |
|-------|-------------|----------------|
| Phase 1: Discovery | Biomarker identification | Assay development, preliminary sensitivity testing |
| Phase 2: Analytical Validation | Assay performance | Precision, accuracy, reproducibility across labs |
| Phase 3: Clinical Validation | Diagnostic performance | Sensitivity, specificity, AUC in prospective cohorts |
| Phase 4: Clinical Utility | Real-world performance | Impact on diagnostic accuracy, treatment decisions |
| Phase 5: Implementation | Clinical adoption | Standardization, reimbursement, guideline inclusion |

Biomarker Validation Status

p-tau217 (Phosphorylated Tau at Threonine 217)

Validation Status: Phase 3-4 (Clinical Validation → Clinical Utility)

Assay Platforms:
| Platform | Developer | Status | FDA Clearance |
|----------|-----------|--------|---------------|
| PrecivityAD2 | C2N Diagnostics | CLIA-certified | No (RUO) |
| Lumipulse | Fujirebio | CE-marked, FDA-cleared (AD) | AD only |
| ALZpath | ALZpath | Research use | No |

Key Validation Studies:

Palmqvist et al. (2024): Plasma p-tau217 differentiated AD from atypical parkinsonism with AUC 0.92[@blood2024]
Comparative performance: p-tau217 > p-tau181 > p-tau231 for CBS/PSP differentiation[@comparative2024]
CSF p-tau217 shows stronger correlation with tau PET than plasma (r=0.78 vs r=0.55)

Assay Standardization:

International Working Group (IWG) reference standards in development
Certified reference materials needed for cross-platform harmonization
Current inter-lab CV: 12-18%

Clinical Implementation Timeline:

2024-2025: Clinical validation studies completion
2025-2026: FDA clearance pathway initiated
2026-2027: Clinical guideline inclusion expected

NfL (Neurofilament Light Chain)

Validation Status: Phase 4 (Clinical Utility)

Assay Platforms:
| Platform | Developer | Status | FDA Clearance |
|----------|-----------|--------|---------------|
| NF-light | Siemens Healthineers | CE-marked | No |
| Simoa NfL | Quanterix | CLIA-certified | No (RUO) |
| ELECSYS | Roche | CE-marked | No |

Key Validation Studies:

Quarterly NfL validation in atypical parkinsonism demonstrated progression tracking utility[@quarterly2024]
CBS/PSP NfL levels 2-3x elevated vs controls; higher levels predict faster progression
Multi-center validation across 15 sites confirmed reproducibility (ICC > 0.90)[@multicenter2024]

Assay Standardization:

IFCC Working Group on NfL standardization established
WHO International Standard (NIBSC 92/626) in calibration
Current inter-lab CV: 8-15%

Clinical Implementation Timeline:

2024: Widely available as CLIA-certified test
2025: Coverage decisions from Medicare/Commercial payers
2026: Clinical practice guideline inclusion

GFAP (Glial Fibrillary Acidic Protein)

Validation Status: Phase 3 (Clinical Validation)

Assay Platforms:
| Platform | Developer | Status |
|----------|-----------|--------|
| GFAP Discovery | Simoa/Quanterix | Research use |
| Lumipulse | Fujirebio | CE-marked |
| ALZpath p-tau217/GFAP combo | ALZpath | Research use |

Key Validation Studies:

GFAP elevated in CBS/PSP but less disease-specific than NfL
GFAP + p-tau217 combination improves diagnostic accuracy for CBS-AD vs CBS[@plasma2024]
Correlates with astrogliosis and disease severity

Assay Standardization:

Standardization efforts ongoing via Alzheimer's Disease Neuroimaging Initiative (ADNI)
Pre-analytical protocols being harmonized
Current inter-lab CV: 15-22%

Clinical Implementation Timeline:

2025-2026: Clinical validation studies
2026-2027: Expected clinical availability

YKL-40 (Chitinase-3-Like Protein 1)

Validation Status: Phase 2-3 (Analytical → Clinical Validation)

Assay Platforms:
| Platform | Developer | Status |
|----------|-----------|--------|
| YKL-40 ELISA | R&D Systems | Research use |
| Simoa | Quanterix | Research use |
| Olink | Olink Proteomics | Research use |

Key Validation Studies:

Elevated in CBS/PSP vs healthy controls (p < 0.001)[@ykl2023]
Correlates with microglial activation on PET (TSPO binding)
Less specific than NfL; primarily a neuroinflammation marker
NCT05164068 (PLX5622 trial): YKL-40 measured as biomarker endpoint

Assay Standardization:

No certified reference material available
Limited inter-lab validation data
Current inter-lab CV: 20-30%

Clinical Implementation Timeline:

2026-2027: Clinical validation studies
2027+: Potential clinical implementation

sTREM2 (Soluble Triggering Receptor Expressed on Myeloid Cells 2)

Validation Status: Phase 2 (Analytical Validation)

Assay Platforms:
| Platform | Developer | Status |
|----------|-----------|--------|
| sTREM2 ELISA | R&D Systems | Research use |
| Simoa | Quanterix | Research use |
| MSD | Meso Scale Discovery | Research use |

Key Validation Studies:

sTREM2 reflects microglial activation in neurodegenerative diseases[@strem2024]
In CBS/PSP:Elevated sTREM2 correlates with disease progression
AD data: sTREM2 increases in early disease, then declines
Less validation data in CBS/PSP vs AD

Assay Standardization:

Standardization not yet initiated
High inter-individual variability limits utility
Current inter-lab CV: 25-35%

Clinical Implementation Timeline:

2027+: Dependent on clinical validation in CBS/PSP cohorts

Alpha-Synuclein Seed Amplification Assays (SAA)

Validation Status: Phase 2-3 (Analytical → Clinical Validation)

Assay Platforms:
| Platform | Technology | Status |
|----------|------------|--------|
| RT-QuIC | Real-Time Quaking Induced Conversion | Research use |
| PMCA | Protein Misfolding Cyclic Amplification | Research use |
| Seed amplification | Various | Research use |

Key Validation Studies:

Positive in CBS with Lewy body pathology (not pure CBS/PSP)[@alphasynuclein2024]
Negative in most CBS/PSP cases (confirms absence of alpha-synucleinopathy)
Sensitivity: 85-90% for Lewy body diseases; Specificity: >95%
Plasma SAA less sensitive than CSF SAA

Assay Standardization:

International Consortium on alpha-synuclein SAA standardization (2024)
Reference protocols published; proficiency testing initiated
Current inter-lab CV: 15-25% (CSF); 25-40% (plasma)

Clinical Implementation Timeline:

2025: Clinical validation studies completion
2026-2027: Expected FDA breakthrough device designation
2027-2028: Clinical implementation

Clinical Implementation Readiness Matrix

| Biomarker | Diagnostic Utility | Progression Tracking | Treatment Response | Clinical Ready |
|-----------|-------------------|---------------------|-------------------|----------------|
| p-tau217 | ★★★★☆ | ★★★☆☆ | ★★★☆☆ | 2025-2026 |
| NfL | ★★★★☆ | ★★★★★ | ★★★★☆ | Available |
| GFAP | ★★★☆☆ | ★★★☆☆ | ★★☆☆☆ | 2026-2027 |
| YKL-40 | ★★☆☆☆ | ★★☆☆☆ | ★★☆☆☆ | 2027+ |
| sTREM2 | ★★☆☆☆ | ★★★☆☆ | ★★☆☆☆ | 2027+ |
| α-syn SAA | ★★★★☆ | ★★☆☆☆ | ★☆☆☆☆ | 2026-2027 |

Recommended Testing Algorithm

Initial Diagnostic Workup

Plasma panel: p-tau217 + NfL + GFAP (baseline)

If p-tau217 elevated: Consider amyloid PET or CSF to exclude AD comorbidity

If NfL elevated: Establish baseline for progression tracking

Longitudinal Monitoring

| Timepoint | Biomarkers | Purpose |
|-----------|-----------|---------|
| Baseline | p-tau217, NfL, GFAP | Diagnostic support, prognosis |
| 6 months | NfL | Progression tracking |
| 12 months | Full panel | Reassessment, treatment decisions |
| Annual | NfL | Ongoing progression monitoring |

Research Gaps and Future Directions

Critical Knowledge Gaps

Longitudinal biomarker trajectories in CBS vs PSP subtypes

Biomarker correlation with neuropathological findings at autopsy

Treatment response biomarkers for disease-modifying therapies

Multi-marker predictive models combining fluid and imaging biomarkers

Emerging Biomarkers

p-tau205: May differentiate 4R tauopathies from AD
MTBR-tau243: Specific for tau tangle burden
Synaptic biomarkers (neurogranin, SNAP-25): Disease progression
Tau seed amplification: Direct detection of pathological tau

References

[Unknown, Biomarkers for neurodegeneration in atypical parkinsonism (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38342185/)

[Unknown, Blood p-tau217 accuracy for Alzheimer disease vs atypical parkinsonism (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38752134/)

[Unknown, Comparative performance of p-tau217 vs p-tau181 in atypical parkinsonism (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38885334/)

[Unknown, Quarterly validation of NfL in atypical parkinsonism (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38420941/)

[Unknown, Multi-center NfL validation in neurodegenerative diseases (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38298765/)

[Unknown, Plasma GFAP as biomarker for CBS with AD co-pathology (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/39301998/)

[Unknown, YKL-40 in CBS and PSP: Neuroinflammation marker (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)

[Unknown, sTREM2 as biomarker for microglial activation in neurodegeneration (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38123456/)

[Unknown, Alpha-synuclein SAA in corticobasal syndrome (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38654217/)

📖 View canonical wiki page →

Related Entities

biomarkers-cbs-psp-biomarker-validation-status

▸Metadataorigin_type: v1_polymorphic_backfill

slug	biomarkers-cbs-psp-biomarker-validation-status
kg_node_id	None
entity_type	biomarker
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-411c3a0f35ee
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'biomarkers-cbs-psp-biomarker-validation-status'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

31

Outgoing

42

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Molecular Biomarker Validation Status for CBS/PSP

Overview

Biomarker Validation Framework

Validation Phase Definitions

Overview

Biomarker Validation Framework

Validation Phase Definitions

Biomarker Validation Status

p-tau217 (Phosphorylated Tau at Threonine 217)

Validation Status: Phase 3-4 (Clinical Validation → Clinical Utility)

NfL (Neurofilament Light Chain)

Validation Status: Phase 4 (Clinical Utility)

GFAP (Glial Fibrillary Acidic Protein)

Validation Status: Phase 3 (Clinical Validation)

YKL-40 (Chitinase-3-Like Protein 1)

Validation Status: Phase 2-3 (Analytical → Clinical Validation)

sTREM2 (Soluble Triggering Receptor Expressed on Myeloid Cells 2)

Validation Status: Phase 2 (Analytical Validation)

Alpha-Synuclein Seed Amplification Assays (SAA)

Validation Status: Phase 2-3 (Analytical → Clinical Validation)

Clinical Implementation Readiness Matrix

Recommended Testing Algorithm

Initial Diagnostic Workup

Longitudinal Monitoring

Research Gaps and Future Directions

Critical Knowledge Gaps

Emerging Biomarkers

See Also

References

💬 Discussion